UBS Group’s AC Immune ACIU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $204K | Sell |
85,614
-16,015
| -16% | -$44.1K | ﹤0.01% | 6782 |
|
|
2026
Q1 | $279K | Sell |
101,629
-92,720
| -48% | -$288K | ﹤0.01% | 6443 |
|
|
2025
Q4 | $610K | Buy |
194,349
+177,925
| +1,083% | +$561K | ﹤0.01% | 5959 |
|
|
2025
Q3 | $47.5K | Buy |
16,424
+8,957
| +120% | +$20.2K | ﹤0.01% | 7598 |
|
|
2025
Q2 | $15.2K | Sell |
7,467
-9,221
| -55% | -$16K | ﹤0.01% | 8625 |
|
|
2025
Q1 | $31.2K | Sell |
16,688
-32,990
| -66% | -$83.1K | ﹤0.01% | 7919 |
|
|
2024
Q4 | $134K | Buy |
49,678
+35,050
| +240% | +$110K | ﹤0.01% | 6691 |
|
|
2024
Q3 | $55.3K | Sell |
14,628
-1,512
| -9% | -$5.28K | ﹤0.01% | 6751 |
|
|
2024
Q2 | $64.4K | Sell |
16,140
-7,525
| -32% | -$24.9K | ﹤0.01% | 6488 |
|
|
2024
Q1 | $70K | Sell |
23,665
-21,335
| -47% | -$76.5K | ﹤0.01% | 6362 |
|
|
2023
Q4 | $225K | Buy |
45,000
+2,026
| +5% | +$6.51K | ﹤0.01% | 5714 |
|
|
2023
Q3 | $122K | Buy |
42,974
+100
| +0.2% | +$304 | ﹤0.01% | 5696 |
|
|
2023
Q2 | $127K | Hold |
42,874
| – | – | ﹤0.01% | 5827 |
|
|
2023
Q1 | $100K | Hold |
42,874
| – | – | ﹤0.01% | 5904 |
|
|
2022
Q4 | $87.5K | Sell |
42,874
-12,992
| -23% | -$33.5K | ﹤0.01% | 6230 |
|
|
2022
Q3 | $176K | Buy |
55,866
+1,041
| +2% | +$3.28K | ﹤0.01% | 5203 |
|
|
2022
Q2 | $198K | Buy |
54,825
+36,000
| +191% | +$123K | ﹤0.01% | 4915 |
|
|
2022
Q1 | $75K | Sell |
18,825
-73,669
| -80% | -$319K | ﹤0.01% | 6110 |
|
|
2021
Q4 | $457K | Buy |
92,494
+71,179
| +334% | +$414K | ﹤0.01% | 5048 |
|
|
2021
Q3 | $143K | Buy |
21,315
+20,162
| +1,749% | +$144K | ﹤0.01% | 5570 |
|
|
2021
Q2 | $10K | Buy |
1,153
+328
| +40% | +$2.27K | ﹤0.01% | 8025 |
|
|
2021
Q1 | $6K | Sell |
825
-3,197
| -79% | -$22.8K | ﹤0.01% | 8218 |
|
|
2020
Q4 | $21K | Buy |
4,022
+3,197
| +388% | +$16.3K | ﹤0.01% | 6906 |
|
|
2020
Q3 | $4K | Sell |
825
-2,000
| -71% | -$14.4K | ﹤0.01% | 7382 |
|
|
2020
Q2 | $19K | Buy |
2,825
+2,000
| +242% | +$14.5K | ﹤0.01% | 6582 |
|
|
2020
Q1 | $6K | Sell |
825
-1,080
| -57% | -$8.44K | ﹤0.01% | 7205 |
|
|
2019
Q4 | $16K | Buy |
1,905
+672
| +55% | +$4.48K | ﹤0.01% | 7018 |
|
|
2019
Q3 | $6K | Sell |
1,233
-2,532
| -67% | -$13.6K | ﹤0.01% | 7387 |
|
|
2019
Q2 | $21K | Sell |
3,765
-343
| -8% | -$1.75K | ﹤0.01% | 6575 |
|
|
2019
Q1 | $21K | Buy |
4,108
+3,283
| +398% | +$20.9K | ﹤0.01% | 6262 |
|
|
2018
Q4 | $8K | Sell |
825
-1,694
| -67% | -$16K | ﹤0.01% | 7332 |
|
|
2018
Q3 | $21K | Buy |
+2,519
| New | +$25.3K | ﹤0.01% | 6766 |
|
|
2018
Q2 | – | Sell |
-2,119
| Closed | -$22K | – | 7937 |
|
|
2018
Q1 | $22K | Buy |
2,119
+2,057
| +3,318% | +$25K | ﹤0.01% | 6340 |
|
|
2017
Q4 | $1K | Buy |
+62
| New | +$730 | ﹤0.01% | 7687 |
|
|
2017
Q3 | – | Sell |
-1,157
| Closed | -$10K | – | 7679 |
|
|
2017
Q2 | $10K | Buy |
+1,157
| New | +$10.7K | ﹤0.01% | 6763 |
|
|
2016
Q4 | – | Sell |
-1,537
| Closed | -$25K | – | 7741 |
|
|
2016
Q3 | $25K | Buy |
+1,537
| New | +$26.6K | ﹤0.01% | 6086 |
|
Other funds holding ACIU
UBS Group's ACIU Position: Q2 2026 in Review
UBS Group reduced its AC Immune (ACIU) stake by 16% in Q2 2026, selling an estimated $44.1K and leaving 85,614 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #6782.
UBS Group first reported a position in ACIU in Q3 2016 and has held it in 36 quarters since. The position peaked at $610K in Q4 2025. 40 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.
- UBS Group held 85,614 shares of AC Immune worth $204K as of Q2 2026.
- UBS Group sold 16,015 AC Immune shares in Q2 2026, an estimated $44.1K.
- AC Immune made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6782 holding.
- UBS Group first reported a position in AC Immune in Q3 2016 and has held it in 36 quarters since.
- UBS Group's AC Immune position peaked at $610K in Q4 2025.
- 40 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.